Serum levels of hsa‐miR‐16‐5p, hsa‐miR‐29a‐3p, hsa‐miR‐150‐5p, hsa‐miR‐155‐5p and hsa‐miR‐223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Casabonne, Delphine; Benavente, Yolanda; Seifert, Julia; Costas, Laura; Armesto, María; Arestin, María; Besson, Caroline; Hosnijeh, Fatemeh Saberi; Duell, Eric J.; Weiderpass, Elisabete; Masala, Giovanna; Kaaks, Rudolf; Canzian, Federico; Chirlaque, María‐Dolores; Perduca, Vittorio; Mancini, Francesca Romana; Pala, Valeria; Trichopoulou, Antonia; Karakatsani, Anna; Vecchia, Carlo La; Sánchez, María‐José; Tumino, Rosario; Gunter, Marc J.; Amiano, Pilar; Panico, Salvatore; Sacerdote, Carlotta; Schmidt, Julie A.; Boeing, Heiner; Schulze, Matthias B.; Barricarte, Aurelio; Riboli, Elio; Olsen, Anja; Tjønneland, Anne; Vermeulen, Roel; Nieters, Alexandra; Lawrie, Charles H.; Sanjosé, Sílvia de

doi:10.1002/ijc.32894

Cited by 29 publications

(18 citation statements)

References 49 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…TCL1 induces AKT activation and inhibits DNA methyltransferases Dnmt3A and Dnmt3B, reducing DNA methylation in CLL cells [173,174]. MiR-29 family deregulation has been specially revealed in exosomes from plasma of CLL patients, as mentioned above [51], and could therefore be employed as a useful biomarker for CLL diagnosis and progression. However, a recent study showed that all miR-29 family members (miR-29a, miR-29b, and miR-29c) were consistently downregulated in the CLL microenvironment as a consequence of BCR activation and seemed to correlate with a significantly shorter overall survival of CLL patients.…”

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 96%

See 1 more Smart Citation

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

Anelli

Zagaria

Specchia

et al. 2021

IJMS

View full text Add to dashboard Cite

Micro RNAs (miRNAs) are a class of small non-coding RNAs that have a crucial role in cellular processes such as differentiation, proliferation, migration, and apoptosis. miRNAs may act as oncogenes or tumor suppressors; therefore, they prevent or promote tumorigenesis, and abnormal expression has been reported in many malignancies. The role of miRNA in leukemia pathogenesis is still emerging, but several studies have suggested using miRNA expression profiles as biomarkers for diagnosis, prognosis, and response to therapy in leukemia. In this review, the role of miRNAs most frequently involved in leukemia pathogenesis is discussed, focusing on the class of circulating miRNAs, consisting of cell-free RNA molecules detected in several body fluids. Circulating miRNAs could represent new potential non-invasive diagnostic and prognostic biomarkers of leukemia that are easy to isolate and characterize. The dysregulation of some miRNAs involved in both myeloid and lymphoid leukemia, such as miR-155, miR-29, let-7, and miR-15a/miR-16-1 clusters is discussed, showing their possible employment as therapeutic targets.

show abstract

Section: Chronic Lymphocytic Leukemiamentioning

confidence: 96%

“…A recent study investigated whether serum levels of miRNAs can be used as a predictive biomarker of CLL. It was found that miR-29a, miR-150-5p, and miR-155-5p were upregulated in the early stages of CLL, but that these miRNAs were poor predictive biomarkers of CLL risk [51].…”

Section: Circulating Mirnasmentioning

confidence: 99%

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

Anelli

Zagaria

Specchia

et al. 2021

IJMS

View full text Add to dashboard Cite

show abstract

“… TB Premix Ex Taq [ 32 ] Lung cancer 40 pairs of tumor tissues and ANCTs Upregulation in Linc00210 (which sponges miR-16-5p) SYBR Premix Ex Taq II and Perfect Real Time [ 34 ] 31 pairs of tumor tissues and ANCTs Upregulation in XIST (which sponges miR-16-5p) SYBR Green Master Mix [ 35 ] Colorectal cancer 72 pairs of tumor tissues and ANCTs Upregulation in PVT1 (which sponges miR-16-5p) Lower OS Upregulation in PVT1 was significantly correlated with lymph node metastasis, distant metastasis, and TNM (tumor, node, metastasis) stage SYBR Green [ 36 ] 42 pairs of tumor tissues and ANCTs Upregulation in ALDH1A3 (a target of miR-16-5p) Lower OS [ 37 ] GEO database: GSE75970, GSE74602, GSE89076, and GSE10950 Upregulation in ITGA2 (a target of miR-16-5p) [ 38 ] Chronic lymphocytic leukemia 224 CLL cases and 224 matched controls miR-16-5p levels were unrelated to CLL risk. TaqMan probes [ 49 ] Chondrosarcoma 9 human chondrosarcoma tissues and 9 normal cartilage Downregulation in miR-16-5p [ 42 ] Giant cell tumor of bone …”

Section: Introductionmentioning

confidence: 99%

A review on the role of mir-16-5p in the carcinogenesis

et al. 2022

View full text Add to dashboard Cite

AbstractmiR-16-5p is microRNA with important roles in the development of diverse malignancies including neuroblastoma, osteosarcoma, hepatocellular carcinoma, cervical cancer, breast cancer, brain tumors, gastrointestinal cancers, lung cancer and bladder cancer. This miRNA has 22 nucleotides. hsa-miR-16-5p is produced by MIR16-1 gene. First evidence for its participation in the carcinogenesis has been obtained by studies reporting deletion and/or down-regulation of these miRNAs in chronic lymphocytic leukemia. Subsequent studies have shown down-regulation of miR-16-5p in a variety of cancer cell lines and clinical samples. Besides, tumor suppressor role of miR-16-5p has been verified in animal models of different types of cancers. Studies in these models have shown that over-expression of this miRNA or modulation of expression of lncRNAs that sponge this miRNA can block carcinogenic processes. In the current review, we summarize function of miR-16-5p in the development and progression of different cancers.

show abstract

“…Leukemia and lymphoma are malignant tumors, having complicated etiology, in whose development and progression miRNAs and benzene exposure play roles. MiRNAs can act as oncogenes in the initiation and progression of leukemia and lymphoma, such as miR‐223, miR‐155, [ 26 ] miR‐146a, [ 27 ] and miR‐125. [ 28–31 ] MiR‐223 is a hematopoietic lineage cell‐specific miRNA, [ 32 ] it regulates NFI‐A, [ 33 ] E2F1, [ 34 ] and IKK‐α [ 35 ] in leukemia via binding to their 3′‐untranslational regions.…”

Section: Introductionmentioning

confidence: 99%

PARP‐1 modulates the expression of miR‐223 through histone acetylation to involve in the hydroquinone‐induced carcinogenesis of TK6 cells

Ling

Pan

Zhang

et al. 2022

J Biochem & Molecular Tox

View full text Add to dashboard Cite

The upstream regulators of microRNAs were rarely reported. Hydroquinone (HQ) is the main metabolite of benzene, one of the important environmental factors contributing to leukemia and lymphoma. In HQ-induced malignant transformed TK6 (TK6-HT) cells, the expression of PARP-1 and miR-223 were upregulated. When in PARP-1 silencing TK6-HT cells, miR-223 was downregulated and the apoptotic cell number correspondingly increased. In TK6 cells treated with HQ for different terms, the expression of miR-223 and PARP-1 were dynamically observed and found to be decreased and increased, respectively. Trichostatin A could increase the expression of miR-223, then the expression of HDAC1-2 and nuclear factor kappa B were found to be increased, but that of mH2A was decreased. PARP-1 silencing inhibited the protein expression of H3Ac, mH2A, and H3K27ac. By co-immunoprecipitation experiment, PARP-1 and HDAC2 were found to form a regulatory complex. In conclusion, we demonstrated that the upregulation of PARP-1 mediated activation of acetylation to promote the transcription of miR-223 possibly via coregulating with HDAC2, an epigenetic regulation mechanism involved in cell malignant transformation resulting from long-term exposure to HQ, in which course, H3K27ac might be a specific marker for the activation of histone H3, which also gives hints for benzene exposure research.

show abstract

Serum levels of hsa‐miR‐16‐5p, hsa‐miR‐29a‐3p, hsa‐miR‐150‐5p, hsa‐miR‐155‐5p and hsa‐miR‐223‐3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Abstract: Serum levels of hsa-miR-16-5p, hsa-miR-29a-3p, hsa-miR-150-5p, hsa-miR-155-5p and hsa-miR-223-3p and subsequent risk of chronic lymphocytic leukemia in the EPIC study

Cited by 29 publications

References 49 publications

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers

A review on the role of mir-16-5p in the carcinogenesis

PARP‐1 modulates the expression of miR‐223 through histone acetylation to involve in the hydroquinone‐induced carcinogenesis of TK6 cells

Contact Info

Product

Resources

About